NCT02353754View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section

PHASE4TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

June 30, 2015

Study Completion Date

July 31, 2015

Conditions
Pain
Interventions
DRUG

Intrathecal morphine injection

0.2 mg

DRUG

EXPAREL

266 mg

Trial Locations (5)

10467

Montefiore, The Bronx

34987

Tradition Medical Center, Port Saint Lucie

43210

The Ohio State University, Wexner Medical Center, Columbus

55455

University Of Minnesota, Minneapolis

08901

Saint Peter's University Hospital, New Brunswick

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY

NCT02353754 - Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section | Biotech Hunter | Biotech Hunter